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Abstract - Leflunomide is an immunosuppressive drug effective in experimental models of transplantation and autoim-
mune diseases and in the treatment of active rheumatoid arthritis (RA). Having in mind that it has been shown that some 
other immunosuppressive drugs (glucocorticoids, mycophenolate mofetil, sirolimus etc.) impair dendritic cell (DC) phe-
notype and function, we investigated the effect of A77 1726, an active metabolite of leflunomide, on the differentiation 
and function of human monocyte-derived dendritic cells (MDDC) in vitro. Immature MDDC were generated by cultivat-
ing monocytes in medium supplemented with GM-CSF and IL-4. To induce maturation, immature MDDC were cultured 
for 2 additional days with LPS. A77 1726 (100 µM) was added at the beginning of cultivation. Flow cytometric analysis 
showed that MDDC differentiated in the presence of A77 1726 exhibited an altered phenotype, with a down-regulated 
surface expression of CD80, CD86, CD54 and CD40 molecules. Furthermore, the continuous presence of A77 1726 dur-
ing differentiation and maturation prevented successful maturation, judging by the decreased expression of maturation 
marker CD83, costimulatory and adhesive molecules on A77 1726-treated mature MDDC. In addition, A77 1726-pre-
treated MDDC exhibited a poor stimulatory capacity of the allogeneic T cells and a low production of IL-10 and IL-18. 
These data suggest that leflunomide impairs the differentiation, maturation and function of human MDDC in vitro, which 
is an additional mechanism of its immunosuppressive effect.   
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INTRODUCTION
Leflunomide is a well-known immunoregulatory 
and disease-modifying anti-rheumatic drug that is 
structurally different from other immunosuppres-
sive agents (Bartlett and Schleyerbach, 1985; Bar-
tlett, 1986; Bartlett et al., 1996; Brazelton and Mor-
ris, 1996). This isoxazole derivate has been shown 
as a potent inhibitor of T- and B-cell proliferation 
without evident cytotoxic activity (Siemasko et al., 
1996; Elder et al., 1997). After oral administration, 
leflunomide is almost completely converted to its ac-
tive metabolite, termed A77 1726, chemically (2Z)-
2-cyano-3-hydroxy-N-[4-(trifluoromethyl) phenyl] 
but-2-enamide. The metabolite is a potent inhibi-
tor of the enzyme dihydroorotate dehydrogenase 
(DHODH), a key enzyme in the de novo synthesis of 
uridine monophosphate (Davis et al., 1996; William-
son et al., 1996). De novo synthesis of pyrimidines is 
not only essential for RNA and DNA synthesis and 
thus the clonal expansion of activated lymphocytes, 
but also for phospholipid synthesis and protein gly-
cosylation (Allison et al., 1993; Cherwinski et al., 
1995). In addition, at least five structurally different 
tyrosine kinases, predominantly expressed in T cells, 
have so far been described as targets of A77 1726 in-
hibition. Many of them are involved in antigen re-
ceptor and growth factor receptor signaling events 
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(Mattar et al., 1993; Xu et al., 1995; Xu et al., 1996; 
Elder et al., 1997). However, A77 1726 is a 150- to 
900-fold more potent inhibitor of DHODH than ty-
rosine kinases (Williamson et al., 1996; Knecht and 
Loffler, 1998).
Although leflunomide has been approved for the 
treatment of rheumatoid arthritis (RA), experiments 
performed on different animal models showed that 
A77 1726 and two other leflunomide metabolites 
with much shorter plasma half-lives (FK 778 and FK 
779) were effective immunosuppressants in experi-
mental organ transplantation (Lirtzman et al., 1996; 
Lucien et al., 1996; Lin et al., 1998).
Alloreactivity is a complex immunological phe-
nomenon associated with the recognition of alloanti-
gens, activation of alloreactive T cells and their differ-
entiation into effectors, which reject the transplanted 
graft. In these processes the cross-talk interplay be-
tween antigen-presenting cells (APC) and T-cells is 
of crucial importance. Among APC, dendritic cells 
(DC) are the only APC with the ability to stimulate 
naive T cells. DC are a heterogeneous population in 
terms of their phenotype, function, maturation stage 
and migration pattern. Myeloid DC that could be 
easily generated in vivo from monocytes are the best-
characterized DC subset, usually assessed as stimu-
lators in the allogeneic MLR. Based on previous ob-
servations that A77 1726 is able not only to inhibit T 
cell proliferation, but also to interfere with cell-cell 
contact and cell adhesion, we postulated that the me-
tabolite of leflunomide also affects DC (Dimitrijevic 
and Bartlett, 1996).
In this work we showed that A77 1726 impairs 
the differentiation and maturation of human mono-




Human recombinant granulocyte macrophage-
colony stimulating factor (GM-CSF) (Leucomax, 
spec. activity 4.44x106 IU) was obtained from San-
doz-Schering Plough, Basle, Switzerland. Human 
recombinant interleukin (IL)-4 was from Roche Di-
agnostics GmbH, Mannheim, Germany. A77 1726, a 
leflunomide metabolite, was obtained from Hoecht 
Marion Roussel, Germany. Stock solutions were pre-
pared by dissolving the drug in RPMI-1640 serum 
free medium (ICN, Costa Mesa, CA). Aliquots were 
kept frozen at –20°C. Lypopolysaccharide (LPS) was 
from Sigma, Munich, Germany.
DC cultures
Highly enriched monocytes (about 75-85 % purity) 
were purified from the buffy coats of healthy volun-
teers by a Lymphoprep gradient (Nycomed, Oslo, 
Norway) and plastic adherence as described (Čolić et 
al., 2003; Čolić et al., 2004). Monocytes were cultivat-
ed for 6-7 days in 4-well tissue culture plates (Flow, 
Irvine, Scotland) in 4 ml of complete RPMI-1640, 
HEPES/sodium bicarbonate buffered medium with 
the addition of 10% heat-inactivated fetal calf serum 
(FCS) (ICN, Costa Mesa, CA), streptomycin, gen-
tamicin, penicillin and 2-ME (Sigma, Munich, Ger-
many). The medium was supplemented with 100 ng/
ml of GM-CSF and 5 ng/ml of IL-4. After day 3, the 
cultures were fed with 3 ml of fresh medium with cy-
tokines. On day 6 (or in some experiments on day 7), 
non-adherent cells (predominantly immature DC) 
were transferred to new plates and half the medium 
was replaced with cytokines or cytokines with 1 µg/
ml LPS. The cells were cultivated for an additional 2 
days. In the cultures with A77 1726, the compound 
was added at different concentrations at the begin-
ning of monocyte cultivation and at the time of me-
dium replacement. 
Flow cytometry
Immature or mature non-adherent MDDC cultivated 
with or without A77 1726 were collected, washed in 
PBS with 0.1% sodium azide and 2% FCS (PBS/FCS) 
and adjusted at concentrations of 1-2 x 105 cells/tube. 
The cells were stained in suspension using appropri-
ate dilutions of the following monoclonal antibod-
ies (mAbs) to: HLA-DR (Becton-Dickinson), CD1a, 
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CD40, CD54, CD80, CD83 and CD86 (Serotec), 
CD14 (ICN). CD1a and CD80 mAbs were conjugat-
ed with FITC, CD86 with PE, whereas other mAbs 
were unconjugated. After washing in PBS/FCS, an 
anti-mouse (Fab-2) Ig-FITC antibody (Serotec) with 
5% normal human serum was added to the cells 
previously incubated with unconjugated mAbs. The 
control consisted of samples with irrelevant mouse 
mAbs reactive with rat antigens. After washing, the 
cells were analyzed on an EPICS XL-MCL flow cy-
tometer (Coulter, Krefeld, Germany). At least 5000 
events were analyzed.
Cytokine assays
After 6 days of cultivation, control immature MDDC 
and A77 1726-treated MDDC were replated (6 x 105 
cells/ml) in complete medium with cytokines and 
LPS or LPS and A77 1726. The cells were cultivated 
for 2 days and supernatants were collected. TNF-α 
was determined using the L929 cytotoxic assay as de-
scribed (Hay and Cohen, 1989). IL-10, IL-12 and IL-
18 were determined using a sandwich ELISA assay 
following the instructions of the manufacturers. The 
IL-10 and IL-12 ELISA kits were from R&D (Min-
neapolis, USA) and IL-18 was from MBL (Nagoya, 
Japan). Detection limits were 0.5 pg/ml for IL-12, 3.9 
pg/ml for IL-10, 12.5 pg/ml for IL-18, and 23.5 pg/
ml for TNF-α.
Effect of A77 1726 on allogeneic lymphocytes prolif-
eration (two-way MLR and allogeneic MLR)
Peripheral blood mononuclear cells (PBMNC) were 
isolated from the buffy coats using a Lymphoprep 
gradient. In some experiments, the T cells were puri-
fied from PBMNC using immunomagnetic sorting 
with a pan-T cell isolation kit by MACS technology 
(Myltenyi Biotec, Bergish Gladbach, Germany), fol-
lowing the instructions of the manufacturer. The pu-
rity of the T cells recovered in the negative fraction 
was higher than 95%, as checked by anti-CD3 FITC 
mAb (Serotec) and flow cytometry. 
To test the effects of the increasing doses of A77 
1726 on allogeneic T cell proliferation, a total of 2 x 
105 purified T cells were stimulated in a 96-well plate 
either by allogeneic lymphocytes (2 x 105) or 2.5 x 103 
immature MDDC or mature MDDC in the absence 
or presence of A77 1726 (10-200 μM). After this, 
we assessed the allostimulatory capacity of the A77 
1726-treated MDDC, immature or mature, on allo-
geneic T cell stimulation. MDDC as stimulators were 
cocultured with 2 x 105 responders in flat-bottom 96-
well microtiter plates. The different DC/T cells ratios 
were used. After 5 days of culture, and in order to 
assess cell proliferation, the cells were pulsed with 
[3H]-thymidine for the last 18 h (1 μCi/well, Am-
ersham, Books, UK). Labeled cells were harvested 
onto glass fiber filters. Radioactivity was counted in a 
Beckman scintillation counter and expressed as cpm 
± SD of triplicates. 
Statistical analysis
Differences in parameters between the control and 
the A77 1726-treated MDDC were evaluated using 
the Mann-Whitney U-test. A p value less than 0.05 
were considered significant.
RESULTS
A77 1726 impairs differentiation of MDDC
The first part of this work was designed to study the 
effect of A77 1726 on the in vitro differentiation of 
MDDC. Blood monocytes (mostly CD14+ CD1a-) 
(Fig. 1A) were cultivated for 7 days in a DC culture 
medium (RPMI+10% FCS supplemented with GM-
CSF and IL-4) alone (Fig. 1B), or with the addition of 
different concentrations of A77 1726 (25 – 200 μM) 
(Fig. 1C-F). Our preliminary experiments showed 
that after 7 days 70-85% of the monocytes developed 
into non-adherent veiled cells, whereas 15-30% cells 
remained adherent, macrophage-like cells. To check 
cell yields in the A77 1726-treated cultures, we col-
lected non-adherent and adherent cells. The cell yield 
was only marginally reduced in the cultures using 25 
μM, 50 μM and 100 μM concentrations of A77 1726, 
whereas the concentration of 200 μM was cytotoxic 
and resulted in about 40% cell recovery (data not 
shown).
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In the control cultures, about 70% of the cells ex-
pressed CD1a, a DC marker, whereas 30% expressed 
CD14, a monocyte/macrophage marker (Fig.1B). The 
absence of CD83 expression (data not shown) sug-
gests that most cells were immature DC. A77 1726 
reduced the expression of CD1a in a dose-dependent 
manner. In contrast, with the lowest concentration 
of the metabolite (25 μM) an increase in the percent-
age of the CD14+ cells was observed, followed by a 
gradual decrease in expression with increasing con-
centrations of A77 1726 (Fig. 1C-F).
 Based on the FS/SS profile (Fig. 1), cells cul-
tivated in the presence of A77 1726 became smaller, 
had less branching and fewer veiled structures and 
a lower FS profile compared to the control MDDC. 
Cumulatively, these results suggest that the lefluno-
mide metabolite at concentrations between 25 μM 
and 100 μM impairs the differentiation of MDDC 
without significant cytotoxic effect. Therefore, in the 
next experiments, we mostly used the 100 μM con-
centration of A77 1726.
 Phenotypic analysis of MDDC cultured for 
9 days in control DC medium or DC medium with 
addition of A77 1726 is presented in Fig. 2A. Con-
trol, immature MDDC were strongly positive for 
HLA-DR (97.4 ± 2.2%; MIF 70.8 ± 7.6 ), CD40, 
CD54 and CD86, and expressed a moderate level 
of CD80. Only a small subset of these cells were 
CD83+ (10.4 ± 4.2%). A77 1726 significantly inhib-
ited the percentage of cells expressing CD80 (47% 
of inhibition) or MIF for CD40, CD54 and CD86. 
Expression of CD83 was almost undetectable while 
HLA-DR was not significantly changed compared to 
control. 
A77 1726 inhibits maturation of MDDC
Immature MDDC generated in the presence of GM-
CSF and IL-4 were induced to mature at day 7 by 
the addition of LPS. At day 9 the phenotype of the 
cells was analyzed. The results presented in Fig. 2B 
show that the maturation of MDDC was followed by 
upregulation of CD83, CD80, CD86, HLA-DR (98.4 
± 1.3%; MIF 154.2 ± 13) and CD54 on the MDDC, 
whereas the expression of the CD40 marker was not 
significantly changed compared to immature MDDC 
(Fig. 2A i B).
 The addition of LPS to the A77 1726-treated 
immature MDDC cultures resulted in the inhibi-
tion of MDDC maturation. The phenomenon was 
confirmed by a significant down-regulation of the 
maturation marker CD83 and decreased MIF for 
CD80 and CD54 molecules. The reduced percent-
age of cells expressing CD80 and decreased density 
of CD86 and CD40 were measured in the A77 1726 
samples after stimulation with LPS, but these differ-
ences did not reach statistical significance. A77 1726 
treatment had no influence on HLA-DR expression 
or MIF (Fig. 2B). 
A77 1726 blocks proliferation of allogeneic lym-
phocytes and significantly decreases allostimulatory 
capacity of MDDC
Leflunomide has been shown to be a potent inhibitor 
of lymphocyte proliferation. This is confirmed in our 
experiments using classical two-way MLR. As can be 
seen in Fig. 3A, the inhibition of proliferation of al-
logeneic lymphocytes was about 60% using a 10 µM 
concentration of A77 1726, whereas concentrations 
between 100 µM and 200 µM almost completely 
blocked cell proliferation. A similar, dose-response 
effect of the leflunomide metabolite on the prolifera-
tion of allogeneic lymphocytes was seen using im-
mature and mature MDDC as stimulators (Fig. 3B). 
MDDC cultivated with A77 1726 (100 µM) showed 
a decreased allostimulatory capacity using purified 
T cells (Fig. 3C, D) as responders. The effect was ob-
served with both the immature MDDC treated with 
A77 1726, and in A77 1726-treated MDDC induced 
to mature with LPS; it was stronger at higher DC/
lymphocyte ratios.
A77 1726 modulates cytokines production by mature 
MDDC
During maturation MDDC secrete various cytokine, 
but some of them, such as IL-12 and IL-10, are very 
important because they induce the Th1 and Th2 
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immune response, respectively. We found that A77 
1726 reduced IL-10 and IL-18 secretion and had 
no influence on measured IL-12 and TNF-α levels, 
compared to the control, mature MDDC (Table 1).
DISCUSSION
Immunosuppressive agents are used to control allo-
graft rejection and to inhibit lymphocyte activation 
and proliferation in the treatment of autoimmune 
diseases. In recent years, evidence has accumulated 
that these diversely acting agents also affect the de-
velopment and functional immunobiology of den-
dritic cells, in vitro and in vivo, by inducing DC 
with a tolerogenic phenotype and function. It has 
been shown that immunosuppressive agents, such 
as glucocorticoids, mycophenolate mofetil (MMF), 
sirolimus and others, impair DC differentiation, 
maturation, allostimulatory capacity and cytokine 
production (Piemonti et al., 1999; Woltman et al., 
2000; Woltman et al., 2001; Čolić et al., 2003). 
It is well known that A77 1726, an active me-
tabolite of a relatively new immunosuppressive drug 
leflunomide, shows antiproliferative and antiadhe-
sive effects. To the best of our knowledge, although 
Dimitrijević et al. showed that the migration of DC 
might be influenced by in vivo administration of 
leflunomide (Dimitrijević et al., 1998), this study 
presents the inhibitory effect of leflunomide on the 
differentiation, maturation and function of human 
MDDC generated in vitro. 
Our work was initiated by preliminary experi-
ments designed to study the effects of different con-
centrations of A77 1726 on in vitro differentiation of 
MDDC. We showed that A77 1726 at concentrations 
between 25 µM and 100 µM impairs differentiation, 
based on the up-regulation of CD1a and down-reg-
ulation of CD14 expression, without a significant 
cytotoxic effect. On the basis of these data and the 
therapeutic plasma concentrations of the active me-
tabolite in patients with RA (100-150 μM), in the 
next experiments we used a 100 µM concentration of 
A77 1726. Phenotypic analysis showed that 80-90% 
of immature MDDC expressed HLA-DR, CD40, 
CD54 and CD86, 47% were CD80 positive, while 
only a small subset was CD83+. The obtained results 
are in agreement with the data showing that DC de 
novo express CD80 and upregulate the expression of 
CD40, HLA-DR, CD4, CD11b, CD11c (Pickl et al., 
1996; Palucka et al., 1998). The continuous presence 
of leflunomide during the differentiation of MDDC 
was followed by a significantly inhibited density of 
co-stimulatory and adhesive molecules on the cell 
surface (CD40, CD54 and C86), and a reduced per-
centage of cell expression of CD80. CD83 was al-
most undetectable, while the other markers were not 
significantly changed. This finding is in accordance 
with the markedly suppressed surface expression of 
CD40 and CD80, and the prevented neo-expression 
of CD1a in leflunomide-treated DC (Kirsch et al. 
2005). The obtained phenotype of A77 1726-treated 
MDDC points to a decreased co-stimulatory and ad-
hesive function of these cells and an unchanged an-
tigen-presenting function, judging by the unaltered 
HLA-DR expression. 
The exposure of immature MDDC to bacterial 
cell products, such as LPS, induced the maturation 
Table 1. Effect of A77 1726 on cytokine production by mature 
MDDC.
pg/ml n mature MDDC A77 1726-treatedMDDC
TNF-α 7 11639 ± 9498 12340 ± 10398
IL-12 6 35 ± 30 26 ± 27
IL-10 6 810 ± 227 285 ± 148*
IL-18 6 29 ± 27 ND
Immature MDDC were obtained by cultivating monocytes with 
GM-CSF and IL-4 for 7 days. A77 1726 (100 μM) was added at 
the beginning of monocyte cultivation. At day 7, non-adherent 
cells were collected, transferred to 6-well plates (5 × 105 cells/ml, 
3 ml/well) and induced to mature by adding LPS (1 μg/ml) to DC 
culture medium with cytokines. A77 1726 was added together 
with LPS in previously A77 1726-treated cultures. After 48 h su-
pernatants are collected and the levels of cytokines were deter-
mined by ELISA (IL-12, IL-10, and IL-18) or bioassay (TNF-β). 
Results are presented as the mean ± SD. 
*p < 0.05 compared to mature MDDC. n-number of donors; 
ND-non-detectable. 
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of DC that was associated with a significant up-
regulation of the maturation marker, CD83, as well 
as other molecules, CD80, CD86, CD54, HLA-DR, 
whereas the expression of CD40 was not significantly 
changed compared to the immature MDDC. Matu-
ration was inhibited in the presence of A77 1726; 
this was confirmed by the lower expression of CD83, 
and 32% of inhibition and down-regulation of CD40, 
CD54, CD80 and CD86. A similar phenotype of DC 
differentiated and activated in the presence of 150 
μM A77 1726 was obtained in the study of Kirsch 
and collaborators (Kirsch et al., 2005). The described 
effects of leflunomide on MDDC differentiation and 
maturation were in correlation with the effect of sev-
eral other immunosuppressive agents published so 
far. Indeed, drugs such as corticosteroids, sirolimus, 
MMF and cyclosporin A inhibited the differentia-
tion, maturation and/or function of human DC (Pie-
monti et al., 1999; Woltman et al., 2000; Woltman et 
al., 2001; Čolić et al., 2003).
The present study also showed that lefluno-
mide efficiently inhibited lymphocyte proliferation 
regardless of which stimulators were used, alloge-
neic lymphocytes, immature or mature MDDC. 
The registered inhibitory effect of A77 1726 in 
classical two-way MLR and allogeneic MLR was 
strong and dose-dependent with almost complete-
ly blocked cell proliferation by higher concentra-
tions of metabolite (100-200 µM). Leflunomide 
exerted an inhibitory effect on lymphocyte prolif-
eration through a direct effect on the lymphocytes 
themselves or by an indirect effect on the MDDC 
as stimulators. As we mentioned before, MDDC 
Fig. 1. A77 1726 impairs in vitro differentiation of human MDDC.
Monocytes isolated from PBMNC were cultivated in (A) RPMI + 10 % FCS medium, (B) DC medium (RPMI + 10 % FCS medium 
supplemented with GM-CSF and IL-4) or DC medium with different concentrations of A77 1726: (C) 25 μM, (D) 50 μM, (E) 100 μM 
and (F) 200 μM. After 7 days, non-adherent and loosely adherent cells that were easily detached by pipetting were collected. Forward 
scatter/side scatter profile and CD1a and CD14 expression were analyzed by flow cytometry.
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cultivated with A77 1726 showed a decreased ex-
pression of costimulatory and adhesive molecules, 
and as consequence of these changes, a lower al-
lostimulatory activity of both immature and ma-
ture A77 1726-treated MDDC in allogeneic MLR 
was observed. It has been published that lefluno-
mide’s antiproliferative effect on lymphocytes is 
a consequence of dihydroorotate dehydrogenase 
inhibition, the enzyme that is necessary for pyri-
midine biosynthesis. In our pilot study (unpub-
lished results), the addition of uridine (100 μM) 
could completely reconstitute the proliferation of 
lymphocytes in two-way MLR and allogeneic ML, 
when leflunomide is used in concentrations less 
that 100 µM. Interestingly, supplementation of 
uridine in the MDDC cultures in the presence of 
Fig. 2. Effect of A77 1726 on phenotypic characteristics of immature and mature MDDC.
(A) Immature MDDC were obtained by cultivating monocytes with GMCSF and IL-4 for 9 days. A77 1726 (100 μM) was added at the 
beginning of monocyte cultivation. (B) To obtain mature MDDC, at day 7, immature MDDC were induced to mature by adding LPS 
(1 μg/ml) to DCs culture medium with cytokines. A77 1726 was added together with LPS in previously A77 1726-treated cultures. At 
day 9 of culture, non-adherent control and A77 1726-treated MDDC were collected, stained in suspension using different MoAbs and 
analyzed by flow cytometry. Values are given as mean percentages of positive cells ± SD and mean fluorescence intensity ± SD calculated 
from four to seven independent experiments. *p < 0.05 compared to control, immature or mature MDDC. 
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Fig. 3. A77 1726 inhibits lymphocytes proliferation induced by different stimulators. 
(A, B) Purified T cells (2 × 105/well) were cultured in a 96-well plate with allogeneic lymphocytes (2 × 105/well), immature MDDC (2, 
5 × 103/well) or mature MDDC (2,5 × 103/well) in the absence or presence of A77 1726 (10-200 μM). After 5 days of culture, to assess 
cell proliferation, cells were pulsed with [3H]-thymidine for last 18 h and the incorporation of the radionuclide into DNA was further 
measured by β-scintillation counting. Data are expressed as the percentage of proliferation inhibition in the presence of A77 1726 com-
pared to corresponding control cultures without drug. The data are from one representative experiment out of three performed. (C, 
D) Immature and mature MDDC were obtained as described in Materials and methods, in the presence or absence of A77 1726 (100 
μM). MDDC were extensively washed and co-cultivated with 2 × 105 allogeneic T cells at different MDDC/T cell ratio. Cell proliferation 
was measured after 5 days using [3H]-thymidine uptake assay. Results are presented as the mean cpm ± SD of triplicate cultures. One 
representative of four experiments is shown.
*p < 0.05; **p < 0.01; ***p < 0.001 compared to control, immature or mature MDDC.
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A77 1726 (100 µM) could not restore the MDDC 
allostimulatory capacity to the control level. Fur-
thermore, the addition of uridine (50 μM) did not 
rescue DC differentiation and maturation, judging 
by obtained phenotype, from the effects of A77 
1726, indicating that the inhibition of DHOD did 
not underlie the observed effects (Kirschet et al., 
2005). Earlier studies performed on lymphocytes 
and some cell lines have established that lefluno-
mide, in concentrations of 100 µM and higher, 
could also act as a tyrosine kinase inhibitor (Mat-
tar et al., 1993; Xu et al., 1995; Xu et al., 1996; Elder 
et al., 1997). The epidermal growth factor receptor 
tyrosine kinase, lck, fyn and Janus kinase (JAK) 1 
and JAK3 were first identified as the targets of A77 
1726 inhibition. Siemasko et al. showed that leflu-
nomide diminished the tyrosine phosphorylation 
of JAK3 and STAT6 in the absence or presence of 
uridine, and blocked IgG1 production (Siemasko 
et al., 1998). Since, it is difficult from our work 
to identify the mechanisms by which leflunomide 
inhibits the differentiation and maturation of 
MDDC, based on the used concentration of A77 
1726 and the effect of added uridine, we could as-
sume that its inhibitory action on tyrosine kinase 
is involved. Indeed, the altered differentiation of 
the MDDC could be the result of the inhibitory 
effect of leflunomide on JAK, a tyrosine kinase in 
the first step of the signal transduction pathway 
activated by numerous cytokines, especially IL-4 
and GM-CSF (Lutz et al., 2002). Furthermore, 
leflunomide could inhibit the NF-kB activation 
(Kirsch et al., 2005) caused by GM-CSF (Ammon 
et al., 2000; Ebner et al., 2003), LPS (Rescigno et 
al., 1998) and TNF-α (Manna et al., 2000) and pre-
vent, in the first place, MDDC maturation and to 
less degree differentiation.
Final functional maturation of MDDC is followed 
by the production of numerous cytokines. Depend-
ing of origin and type, as well as maturation stimu-
lus, DC can produce TNF-α, IL-6, IL10, IL-12, IL-
15, IL-18 and IFN-γ (Verhasselt et al., 1997). In this 
work, LPS-stimulated MDDC produced significantly 
higher levels of TNF-α, IL-12, IL-10 and IL-18 than 
the immature one. TNF-α induces the differentiation 
and maturation of DC, the production of IL-10 by 
activated monocytes and together with PGE2, the 
secretion of IL-12 by human DC (Reiser et al., 1997; 
Foey et al., 1998). IL-12 is a potent pro-inflammatory 
cytokine that plays a central role in the initiation and 
control of cell-mediated immunity as an inducer of 
Th1 response. IL-12-driven Th1 immune response is 
enhanced by IL-18 through the induction of IFN-γ 
(Nakanishi, 2002). In contrast, IL-10 inhibits Th1 de-
velopment, promotes Th2 response or tolerance, and 
exerts negative regulatory roles for a wide variety of 
immune cells (Seewaldt et al., 2002). 
On the one hand, we showed that exposure of 
MDDC to A77 1726 during maturation had no 
influence on the production of TNF-α and IL-12. 
These in vitro data did not correlate with the pub-
lished results of other authors suggesting the in-
hibitory effect of leflunomide on TNF-α production 
by different cell type such as T cells (Deage et al., 
1998), macrophages (Elkayam et al., 2003), MDDC 
(Kirsch et al., 2005) or IL-12 production by MDDC 
(Kirsch et al., 2005). The observed differences could, 
at least, be a consequence of different cultivation 
conditions, concentration of leflunomide metabo-
lite and maturation stimulus or, finally, of the assays 
used for cytokine detection. 
On the other hand, the reduced production of 
IL-10 and IL-18 that has been measured is in accord-
ance with findings showing a decreased IL-10 levels 
in vivo and in vitro after leflunomide treatment (Kir-
sch et al., 2005; Litinsky et al., 2006). Other immuno-
suppressive agents, like cyclosporine A, tacrolimus 
and sirolimus to less degree suppressed or had no 
major effect on IL-12 and IL-10 production, with the 
exception of sirolimus and MMF, which inhibited IL-
10 secretion like leflunomide (Woltman et al., 2000; 
Woltman et al., 2001; Čolić et al., 2003). 
Taken together, our data show that leflunomide, 
in addition to its direct inhibitory action on T cells, 
inhibits the differentiation, maturation and function 
of human MDDC. These findings provide new infor-
mation on the immunosuppressive/immunomodu-
latory function of leflunomide and could in future 
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contribute to the generation of new strategies for the 
therapeutic control of immunopathological reactions 
with an excessive immune response.
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